After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

There is a misconception that experiencing constant breathlessness is a typical part of getting older when this is not the ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

Increasing Prevalence of Asthma and COPD: The rising incidence of asthma and chronic obstructive pulmonary disease (COPD) ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxtm, today announced ...

Please view our advertising policy and product review methodology for more information. Rather than focusing solely on opening new properties for its core brands, Hyatt has continued to acquire and ...